ArticleJournal of immunology (Baltimore, Md. : 1950)2009
A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria.
Article in Journal of immunology (Baltimore, Md. : 1950), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Review
- Synthesis of Chirally Chimeric Protein Nanoparticle Vaccines via Mirror-Image Spy Chemistry.Angewandte Chemie (International ed. in English) · 2025Article
- Review
- Optimized Refolding Buffers Oriented Humoral Immune Responses Versus PfGCS1 Self-Assembled Peptide Nanoparticle.Molecular biotechnology · 2024Article
- Self-assembled peptide/polymer hybrid nanoplatform for cancer immunostimulating therapies.Drug delivery and translational research · 2024Article
- Polypeptide-Based Systems: From Synthesis to Application in Drug Delivery.Pharmaceutics · 2023Review
- Nanotechnology-Based Strategies in Parasitic Disease Management: From Prevention to Diagnosis and Treatment.ACS omega · 2023Review
- CD4Vaccines · 2023Article
- Nanoparticles Carrying Conserved Regions of Influenza A Hemagglutinin, Nucleoprotein, and M2 Protein Elicit a Strong Humoral and T Cell Immune Response and Protect Animals from Infection.Molecules (Basel, Switzerland) · 2023Article
- Nanoadjuvants: Promising Bioinspired and Biomimetic Approaches in Vaccine Innovation.ACS omega · 2023Review
- Plant-Produced Nanoparticles Based on Artificial Self-Assembling Peptide Bearing the Influenza M2e Epitope.Plants (Basel, Switzerland) · 2023Article
- Nanomedicine: New Frontiers in Fighting Microbial Infections.Nanomaterials (Basel, Switzerland) · 2023Review
- Nano toolbox in immune modulation and nanovaccines.Trends in biotechnology · 2022Review
- Peptides for Vaccine Development.ACS applied bio materials · 2022Review
- Article
- Peptide-based supramolecular vaccine systems.Acta biomaterialia · 2021Review
- Prophylactic vaccine delivery systems against epidemic infectious diseases.Advanced drug delivery reviews · 2021Review
- Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health.Nature nanotechnology · 2021Review
- Engineering and characterization of a novel Self Assembling Protein for Toxoplasma peptide vaccine in HLA-A*11:01, HLA-A*02:01 and HLA-B*07:02 transgenic mice.Scientific reports · 2020Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
We have designed and produced a prototypic malaria vaccine based on a highly versatile self-assembling polypeptide nanoparticle (SAPN) platform that can repetitively display antigenic epitopes. We used this platform to display a tandem repeat of the B cell immunodominant repeat epitope (DPPPPNPN)(2)D of the malaria parasite Plasmodium berghei circumsporozoite protein. Administered in saline, without the need for a heterologous adjuvant, the SAPN construct P4c-Mal conferred a long-lived, protective immune response to mice with a broad range of genetically distinct immune backgrounds including the H-2(b), H-2(d), and H-2(k) alleles. Immunized mice produced a CD4(+) T cell-dependent, high-titer, long-lasting, high-avidity Ab response against the B cell epitope. Mice were protected against an initial challenge of parasites up to 6 mo after the last immunization or for up to 15 mo against a second challenge after an initial challenge of parasites had successfully been cleared. Furthermore, we demonstrate that the SAPN platform not only functions to deliver an ordered repetitive array of B cell peptide epitopes but operates as a classical immunological carrier to provide cognate help to the P4c-Mal-specific B cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.